Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for prediction and prognosis of cancer, and monitoring cancer therapy

A prognostic and immune detection technology, applied in the direction of measuring devices, antineoplastic drugs, instruments, etc., can solve the problem of no correlation between reports

Inactive Publication Date: 2009-01-21
BAYER HEALTHCARE LLC
View PDF7 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although measurement of total VEGF-A has been used as a prognostic indicator of disease outcome in humans, no correlation between VEGF levels in patients prior to chemotherapy and treatment outcome has been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for prediction and prognosis of cancer, and monitoring cancer therapy
  • Methods for prediction and prognosis of cancer, and monitoring cancer therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0087] Example 1. Solid Phase Sandwich Microtiter ELISA for Human Serum and Plasma Sample Preparation

[0088] Suitable samples for analysis by VEGF ELISA include human plasma treated with heparin, citrate or EDTA. Special care is required in the preparation and assay of human serum and plasma due to possible interfering factors. Any flocculant material should be removed from the sample by microcentrifugation prior to dilution. The initial concentration of the serum or plasma sample to be examined should be 12-13% (1:8 dilution of sample in sample diluent). For example, 40 μl of sample is diluted in 280 μl of sample diluent and 100 μl is added to a microplate well.

[0089] test methods

[0090] The following ELISA protocol was used in a sandwich ELISA (Oncogene Science, Cambridge, MA) to measure human VEGF in human plasma and serum.

[0091] 1. Prepare the working solution (1X) for plate washing (supplied as part of the assay kit).

[0092] 2. For each sample and standar...

Embodiment 2

[0109] Example 2. Plasma from Renal Cell Carcinoma Patients

[0110] Duplicate samples were used to measure VEGF levels using a VEGF ELISA (R&D Systems, Minneapolis, MN) according to the manufacturer's directions. For each patient, the mean of duplicate measurements was determined. For the patient group treated with sorafenib and the patient group treated with placebo, the mean levels of VEGF at three time points are given in Table 1, the three time points are baseline (pre-treatment), cycle 1 Day 21 and Day 1 of cycle 3. figure 1The same data are shown in . The results showed that the Sorafenib-treated patient group had significantly reduced VEGF levels from baseline at two time points (using paired t test, p 0.05).

[0111] Table 1: VEGF

[0112]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of VEGF as a biomarker for multi-kinase inhibitors.

Description

field of invention [0001] The present invention relates to a biomarker and the use of the biomarker for the prediction and prognosis of cancer and the use of the biomarker to monitor the effect of cancer treatment. In particular, the invention relates to the use of VEGF as a biomarker for multikinase inhibitors. Background of the invention [0002] Vascular endothelial growth factor receptor (VEGFR) and its ligand, vascular endothelial growth factor (VEGF), play key roles in endothelial cell migration and proliferation. The VEGFR / VEGF system includes three receptors (VEGFR-1, VEGFR-2 and VEGFR-3) and four ligands (VEGF-A, B, C, D and E and placental growth factor). VEGF-A further consists of four isoforms, VEGF-121, VEGF-165, VEGF-185 and VEGF-204, which arise from alternative transcription of the VEGF-A gene. Receptors are plasma transmembrane proteins with an intracellular tyrosine kinase domain. Like other protein kinases, activation of VEGFR is a key mechanism for reg...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574
CPCG01N33/57492G01N2800/52G01N2333/71G01N2333/475A61P35/00A61P43/00
Inventor J·J·埃尔廷W·P·卡尼P·J·哈默D·比格伍德
Owner BAYER HEALTHCARE LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com